<!DOCTYPE html><html><head><style>
        /* Create a running element */
        #header-and-footer {
          position: running(header-and-footer);
          text-align: right;
        }

        /* Add that running element to the top and bottom of every page */
        @page {
          @top {
            content: element(header-and-footer);
          }
          @bottom {
            content: element(header-and-footer);
          }
        }

        /* Add a page number */
        #page-number {
          content: "Page " counter(page);
        }

        /* Create a title page with a full-bleed background and no header */
        #title-page {
          page: title-page;
        }

        @page title-page {
          @top {
            content: "";
          }
        }

        #title-page h1 {
          padding: 200px 0 40px 0;
          font-size: 30px;
        }

        /* Dynamically create a table of contents with leaders */
        #table-of-contents a {
          content: target-content(attr(href)) leader('.') target-counter(attr(href), page);
          color: #000000;
          text-decoration: none;
          display: block;
          padding-top: 5px;
        }

        /* Float the footnote to a footnotes area on the page */
        .footnote {
          float: footnote;
          font-size: small;
        }

        .page {
          page-break-after: always;
        }

        body {
          counter-reset: chapter;
          font-family: 'Times New Roman';
          color: #000000;
        }
      </style>
      <link href='https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;600;800&display=swap' rel='stylesheet'>
      </style></head><body>
        <div id="title-page" class="page">
          <h1>Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease</h1>
          <div id="header-and-footer">
            <span id="page-number"></span>
          </div>
        </div>
        <div id="toc-page" class="page">
          <div id="table-of-contents">
            <a href="#section-0"></a><a href="#section-1"></a><a href="#section-2"></a><a href="#section-3"></a><a href="#section-4"></a><a href="#section-5"></a><a href="#section-6"></a><a href="#section-7"></a><a href="#section-8"></a><a href="#section-9"></a><a href="#section-10"></a><a href="#section-11"></a><a href="#section-12"></a><a href="#section-13"></a><a href="#section-14"></a><a href="#section-15"></a>
          </div>
          <div id="header-and-footer">
            <span id="page-number"></span>
          </div>
        </div>
      <div class="page"><table><tr><th style="vertical-align: top; text-align: left"><p>Sponsor Confidentiality Statement:</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Sponsor Confidentiality Statement</span><br/><span style="color: #FA8072">USDM: No mapping path</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Full Title:</p></th><td style="vertical-align: top; text-align: left"><p>Missing content</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Full Title</span><br/><span style="color: #FA8072">USDM: StudyProtocolDocumentVersion/@officialTitle</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Trial Acronym:</p></th><td style="vertical-align: top; text-align: left"><p>Missing content</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter trial Acronym</span><br/><span style="color: #FA8072">USDM: StudyVersion/@studyAcronym</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Protocol Identifier:</p></th><td style="vertical-align: top; text-align: left"><p>H2Q-MC-LZZT</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Protocol Identifier</span><br/><span style="color: #FA8072">USDM: StudyIdentifier[Organization/@type/@code=C70793]/@studyIdentifier</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Original Protocol:</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Original protocol</span><br/><span style="color: #FA8072">USDM: No mapping path</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Version Number:</p></th><td style="vertical-align: top; text-align: left"><p>2</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Version Number</span><br/><span style="color: #FA8072">USDM: StudyVersion/@versionIdentifier</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Version Date:</p></th><td style="vertical-align: top; text-align: left"><p>2006-07-01</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Version Date</span><br/><span style="color: #FA8072">USDM: StudyProtocolDocumentVersion/GovernanceDate[@type/@code=C99903x1]/@dateValue</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Amendment Identifier:</p></th><td style="vertical-align: top; text-align: left"><p>1</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Amendment Identifier</span><br/><span style="color: #FA8072">USDM: StudyVersion/StudyAmendment/@number</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Amendment Scope:</p></th><td style="vertical-align: top; text-align: left"><p>Europe</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Amendment Scope</span><br/><span style="color: #FA8072">USDM: StudyVersion/StudyAmendment/SubjectEnrollment/@code/@standardCode/@decode</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Compound Codes(s):</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Compound Code(s)</span><br/><span style="color: #FA8072">USDM: No mapping path</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Compound Name(s):</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Nonproprietary Name(s), Enter Proprietary Name(s)</span><br/><span style="color: #FA8072">USDM: No mapping path</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Trial Phase:</p></th><td style="vertical-align: top; text-align: left"><p>Phase II Trial</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Trial Phase</span><br/><span style="color: #FA8072">USDM: StudyVersion/@studyPhase/@standardCode/@decode</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Short Title:</p></th><td style="vertical-align: top; text-align: left"><p>Missing content</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Trial Short Title</span><br/><span style="color: #FA8072">USDM: StudyProtocolDocumentVersion/@briefTitle</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Sponsor Name and Address:</p></th><td style="vertical-align: top; text-align: left"><p>Eli Lilly, Lilly Corporate Ctr, Indianapolis, -, IN, 4628, United States of America</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Sponsor Name, Enter Sponsor Legal Address</span><br/><span style="color: #FA8072">USDM: StudyIdentifier[Organization/@type/@code=C70793]/Organization/@name, StudyIdentifier[Organization/@type/@code=C70793]/Organization/Address/@text</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Regulatory Agency Identifier Number(s):</p></th><td style="vertical-align: top; text-align: left"><p>NCT12345678</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: EU CT Number, IDE Number, FDA IND Number, JRCT Number, NCT Number, NMPA IND Number, WHO/UTN Number, Other Regulatory Agency Identifier Number</span><br/><span style="color: #FA8072">USDM: StudyIdentifier[Organization/@type/@code=C188863|C93453]/@studyIdentifier</span></i></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Spondor Approval Date:</p></th><td style="vertical-align: top; text-align: left"><p>2006-06-01</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Approval Date or state location where information can be found</span><br/><span style="color: #FA8072">USDM: StudyVersion/GovernanceDate[@type/@code=C132352]/@dateValue</span></i></td></tr></table></div><div class="page"><h1 id="section-1">1&nbspPROTOCOL SUMMARY</h1><div></div><div class=""><h2 id="section-1.1">1.1&nbspProtocol Synopsis</h2><div></div></div><div class=""><h2 id="section-1.2">1.2&nbspTrial Schema</h2><div></div></div><div class=""><h2 id="section-1.3">1.3&nbspSchedule of Activities</h2><div></div></div></div><div class="page"><h1 id="section-2">2&nbspINTRODUCTION</h1><div></div><div class=""><h2 id="section-2.1">2.1&nbspPurpose of Trial</h2><div></div></div><div class=""><h2 id="section-2.2">2.2&nbspSummary of Benefits and Risks</h2><div></div></div></div><div class="page"><h1 id="section-3">3&nbspTRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS</h1><div></div><div class=""><h2 id="section-3.1">3.1&nbspPrimary Objectives</h2><table><tr><td style="vertical-align: top; text-align: left"><p>To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).</p></td><td style="vertical-align: top; text-align: left"><p>Alzheimer's Disease Assessment Scale - Cognitive Subscale, total of 11 items [ADAS-Cog (11)] at Week 24</p><p>Video-referenced Clinician’s Interview-based Impression of Change (CIBIC+) at Week 24</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>To document the safety profile of the xanomeline TTS.</p></td><td style="vertical-align: top; text-align: left"><p>Adverse events</p><p>Vital signs (weight, standing and supine blood pressure, heart rate)</p><p>Laboratory evaluations (Change from Baseline)</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.</p></td><td style="vertical-align: top; text-align: left"><p>Alzheimer's Disease Assessment Scale - Cognitive Subscale, total of 11 items [ADAS-Cog (11)] at Weeks 8 and 16</p><p>Video-referenced Clinician’s Interview-based Impression of Change (CIBIC+) at Weeks 8 and 16</p><p>Mean Revised Neuropsychiatric Inventory (NPI-X) from Week 4 to Week 24</p></td></tr></table></div></div><div class="page"><h1 id="section-4">4&nbspTRIAL DESIGN</h1><div></div><div class=""><h2 id="section-4.1">4.1&nbspDescription of Trial Design</h2><div></div><div class=""><h3 id="section-4.1.1">4.1.1&nbspParticipant Input into Design</h3><div></div></div></div><div class=""><h2 id="section-4.2">4.2&nbspRationale for Trial Design</h2><div><p>Previous studies of the oral formulation have shown that xanomeline tartrate may improve behavior and cognition. Effects on behavior are manifest within 2 to 4 weeks of initiation of treatment. The same studies have shown that 8 to 12 weeks are required to demonstrate effects on cognition and clinical global assessment. This study is intended to determine the acute and chronic effects of the TTS formulation in AD; for that reason, the study is of 26 weeks duration. Dosage specification has been made on the basis of tolerance to the xanomeline TTS in a clinical pharmacology study (H2Q-EW-LKAA), and target plasma levels as determined in studies of the oral formulation of xanomeline (H2Q-MC-LZZA).</p></div><div class=""><h3 id="section-4.2.1">4.2.1&nbspRationale for Comparator</h3><div><p>The parallel dosing regimen maximizes the ability to make direct comparisons between the treatment groups. The use of placebo allows for a blinded, thus minimally biased, study. The placebo treatment group is a comparator group for efficacy and safety assessment.</p><p>Two interim analyses are planned for this study. The first interim analysis will occur when 50% of the patients have completed Visit 8 (8 weeks). If required, the second interim analysis will occur when 50% of the patients have completed Visit 12 (24 weeks).</p></div></div><div class=""><h3 id="section-4.2.2">4.2.2&nbspRationale for Adaptive or Novel Trial Design</h3><div></div></div><div class=""><h3 id="section-4.2.3">4.2.3&nbspOther Trial Design Considerations</h3><div></div></div></div><div class=""><h2 id="section-4.3">4.3&nbspAccess to Trial Intervention After End of Trial</h2><div></div></div><div class=""><h2 id="section-4.4">4.4&nbspStart of Trial and End of Trial</h2><div></div></div></div><div class="page"><h1 id="section-5">5&nbspTRIAL POPULATION</h1><div></div><div class=""><h2 id="section-5.1">5.1&nbspSelection of Trial Population</h2><div><p>For Lilly studies, the following definitions are used:</p>
<div>
<div><strong>Screen</strong></div>
<div>
<p>Screening is the act of determining if an individual meets minimum requirements to become part of a pool of potential candidates for participation in a clinical study.</p>
<p>In this study, <strong>screening</strong> will include asking the candidate preliminary questions (such as age and general health status) and conducting invasive or diagnostic procedures and/or tests (for example, diagnostic psychological tests, x-rays, blood draws). Patients will sign the consent at their screening visit, thereby consenting to undergo the screening procedures and to participate in the study if they qualify.</p>
</div>
</div>
<div>
<div>To <strong>enter</strong></div>
<div>
<p>Patients <strong>entered</strong> into the study are those from whom informed consent for the study has been obtained. Adverse events will be reported for each patient who has <strong>entered</strong> the study, even if the patient is never assigned to a treatment group (<strong>enrolled</strong>).</p></div>
</div>
</div>
<div>
<div>To <strong>enroll</strong></div>
<div>
<p>Patients who are enrolled in the study are those who have been assigned to a treatment group. Patients who are entered into the study but fail to meet criteria specified in the protocol for treatment assignment will not be enrolled in the study.</p></div>
</div>

<p>At Visit 1, patients who meet the enrollment criteria of Mini-Mental State Examination (MMSE) score of 10 to 23 (Attachment LZZT.6), Hachinski Ischemia Score ≤4 (Attachment LZZT.8), a physical exam, safety labs, ECG, and urinalysis, will proceed to Visit 2 and Visit 3. At Visit 3, patients whose CNS imaging and other pending labs from Visit 1 satisfy the inclusion criteria (Section 3.4.2.1) will be enrolled in the study. Approximately 300 patients with a diagnosis of probable mild to moderate AD will be enrolled in the study.</p></div><div class=""><h2 id="section-5.2">5.2&nbspRationale for Trial Population</h2><div></div></div><div class=""><h2 id="section-5.3">5.3&nbspInclusion Criteria</h2><p>Patients may be included in the study only if they meet <strong>all</strong> the following criteria:</p><table><tr><td style="vertical-align: top; text-align: left"><p>1</p></td><td style="vertical-align: top; text-align: left"><p>Subjects shall be between Missing content and Missing content</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>2</p></td><td style="vertical-align: top; text-align: left"><p>Missing content as defined by the NINCDS and the ADRDA guidelines (Attachment LZZT.7)</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>3</p></td><td style="vertical-align: top; text-align: left"><p>MMSE score of 10 to 23</p></td></tr></table></div><div class=""><h2 id="section-5.4">5.4&nbspExclusion Criteria</h2><p>Patients may be excluded in the study for <strong>any</strong> of the following reasons:</p><table><tr><td style="vertical-align: top; text-align: left"><p>9</p></td><td style="vertical-align: top; text-align: left"><p>Persons who have previously completed or withdrawn from this study or any other study investigating xanomeline TTS or the oral formulation of xanomeline.</p></td></tr></table></div><div class=""><h2 id="section-5.5">5.5&nbspLifestyle Considerations</h2><div></div><div class=""><h3 id="section-5.5.1">5.5.1&nbspMeals and Dietary Restrictions</h3><div></div></div><div class=""><h3 id="section-5.5.2">5.5.2&nbspCaffeine, Alcohol, Tobacco, and Other Habits</h3><div><p>Not applicable</p></div></div><div class=""><h3 id="section-5.5.3">5.5.3&nbspPhysical Activity</h3><div></div></div><div class=""><h3 id="section-5.5.4">5.5.4&nbspOther Activity</h3><div></div></div></div><div class=""><h2 id="section-5.6">5.6&nbspScreen Failures</h2><div></div></div></div><div class="page"><h1 id="section-6">6&nbspTRIAL INTERVENTION AND CONCOMITANT THERAPY</h1><div></div><div class=""><h2 id="section-6.1">6.1&nbspDescription of Trial Intervention</h2><div></div></div><div class=""><h2 id="section-6.2">6.2&nbspRationale for Trial Intervention</h2><div></div></div><div class=""><h2 id="section-6.3">6.3&nbspDosing and Administration</h2><div></div><div class=""><h3 id="section-6.3.1">6.3.1&nbspTrial Intervention Dose Modification</h3><div></div></div></div><div class=""><h2 id="section-6.4">6.4&nbspTreatment of Overdose</h2><div></div></div><div class=""><h2 id="section-6.5">6.5&nbspPreparation, Handling, Storage and Accountability</h2><div></div><div class=""><h3 id="section-6.5.1">6.5.1&nbspPreparation of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-6.5.2">6.5.2&nbspHandling and Storage of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-6.5.3">6.5.3&nbspAccountability of Trial Intervention</h3><div></div></div></div><div class=""><h2 id="section-6.6">6.6&nbspParticipant Assignment, Randomisation and Blinding</h2><div></div><div class=""><h3 id="section-6.6.1">6.6.1&nbspParticipant Assignment</h3><div></div></div><div class=""><h3 id="section-6.6.2">6.6.2&nbspRandomisation</h3><div></div></div><div class=""><h3 id="section-6.6.3">6.6.3&nbspBlinding and Unblinding</h3><div><p>The study will be double-blind. To further preserve the blinding of the study, only a minimum number of Lilly and CRO personnel will see the randomization table and codes before the study is complete.</p>
<p>Emergency codes generated by a computer drug-labeling system will be available to the investigator. These codes, which reveal the patients treatment group, may be opened during the study only if the choice of follow-up treatment depends on the patient’s therapy assignment.</p>
<p>The investigator should make every effort to contact the clinical research physician prior to unblinding a patient’s therapy assignment. If a patient’s therapy assignment is unblinded, Lilly must be notified immediately by telephone. After the study, the investigator must return all sealed and any opened codes.</p></div></div></div><div class=""><h2 id="section-6.7">6.7&nbspTrial Intervention Compliance</h2><div></div></div><div class=""><h2 id="section-6.8">6.8&nbspConcomitant Therapy</h2><div></div><div class=""><h3 id="section-6.8.1">6.8.1&nbspProhibited Concomitant Therapy</h3><div></div></div><div class=""><h3 id="section-6.8.2">6.8.2&nbspPermitted Concomitant Therapy</h3><div></div></div><div class=""><h3 id="section-6.8.3">6.8.3&nbspRescue Therapy</h3><div></div></div><div class=""><h3 id="section-6.8.4">6.8.4&nbspOther Therapy</h3><div></div></div></div></div><div class="page"><h1 id="section-7">7&nbspDISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL</h1><div></div><div class=""><h2 id="section-7.1">7.1&nbspDiscontinuation of Trial Intervention</h2><div></div><div class=""><h3 id="section-7.1.1">7.1.1&nbspCriteria for Permanent Discontinuation of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-7.1.2">7.1.2&nbspTemporary Discontinuation or Interruption of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-7.1.3">7.1.3&nbspRechallenge</h3><div></div></div></div><div class=""><h2 id="section-7.2">7.2&nbspParticipant Withdrawal from the Trial</h2><div></div></div><div class=""><h2 id="section-7.3">7.3&nbspLost to Follow-Up</h2><div></div></div><div class=""><h2 id="section-7.4">7.4&nbspTrial Stopping Rules</h2><div></div></div></div><div class="page"><h1 id="section-8">8&nbspTRIAL ASSESSMENTS AND PROCEDURES</h1><div></div><div class=""><h2 id="section-8.1">8.1&nbspScreening/Baseline Assessments and Procedures</h2><div></div></div><div class=""><h2 id="section-8.2">8.2&nbspEfficacy Assessments and Procedures</h2><div></div></div><div class=""><h2 id="section-8.3">8.3&nbspSafety Assessments and Procedures</h2><div></div><div class=""><h3 id="section-8.3.1">8.3.1&nbspPhysical Examination</h3><div></div></div><div class=""><h3 id="section-8.3.2">8.3.2&nbspVital Signs</h3><div></div></div><div class=""><h3 id="section-8.3.3">8.3.3&nbspElectrocardiograms</h3><div></div></div><div class=""><h3 id="section-8.3.4">8.3.4&nbspClinical Laboratory Assessments</h3><div></div></div><div class=""><h3 id="section-8.3.5">8.3.5&nbspSuicidal Ideation and Behaviour Risk Monitoring</h3><div></div></div></div><div class=""><h2 id="section-8.4">8.4&nbspAdverse Events and Serious Adverse Events</h2><div></div><div class=""><h3 id="section-8.4.1">8.4.1&nbspDefinitions of AE and SAE</h3><div></div></div><div class=""><h3 id="section-8.4.2">8.4.2&nbspTime Period and Frequency for Collecting AE and SAE Information</h3><div></div></div><div class=""><h3 id="section-8.4.3">8.4.3&nbspIdentifying AEs and SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.4">8.4.4&nbspRecording of AEs and SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.5">8.4.5&nbspFollow-up of AEs and SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.6">8.4.6&nbspReporting of SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.7">8.4.7&nbspRegulatory Reporting Requirements for SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.8">8.4.8&nbspSerious and Unexpected Adverse Reaction Reporting</h3><div></div></div><div class=""><h3 id="section-8.4.9">8.4.9&nbspAdverse Events of Special Interest</h3><div></div></div><div class=""><h3 id="section-8.4.10">8.4.10&nbspDisease-related Events or Outcomes Not Qualifying as AEs or SAEs</h3><div></div></div></div><div class=""><h2 id="section-8.5">8.5&nbspPregnancy and Postpartum Information</h2><div></div><div class=""><h3 id="section-8.5.1">8.5.1&nbspParticipants Who Become Pregnant During the Trial</h3><div></div></div><div class=""><h3 id="section-8.5.2">8.5.2&nbspParticipants Whose Partners Become Pregnant</h3><div></div></div></div><div class=""><h2 id="section-8.6">8.6&nbspMedical Device Product Complaints for Drug/Device Combination Products</h2><div></div><div class=""><h3 id="section-8.6.1">8.6.1&nbspDefinition of Medical Device Product Complaints</h3><div></div></div><div class=""><h3 id="section-8.6.2">8.6.2&nbspRecording of Medical Device Product Complaints</h3><div></div></div><div class=""><h3 id="section-8.6.3">8.6.3&nbspTime Period and Frequency for Collecting Medical Device Product Complaints .</h3><div></div></div><div class=""><h3 id="section-8.6.4">8.6.4&nbspFollow-Up of Medical Device Product Complaints</h3><div></div></div><div class=""><h3 id="section-8.6.5">8.6.5&nbspRegulatory Reporting Requirements for Medical Device Product Complaints</h3><div></div></div></div><div class=""><h2 id="section-8.7">8.7&nbspPharmacokinetics</h2><div></div></div><div class=""><h2 id="section-8.8">8.8&nbspGenetics</h2><div></div></div><div class=""><h2 id="section-8.9">8.9&nbspBiomarkers</h2><div></div></div><div class=""><h2 id="section-8.1">8.1&nbspImmunogenicity Assessments</h2><div></div><div class=""><h3 id="section-8.1.1">8.1.1&nbspMedical Resource Utilisation and Health Economics</h3><div></div></div></div></div><div class="page"><h1 id="section-9">9&nbspSTATISTICAL CONSIDERATIONS</h1><div></div><div class=""><h2 id="section-9.1">9.1&nbspAnalysis Sets</h2><div></div></div><div class=""><h2 id="section-9.2">9.2&nbspAnalyses Supporting Primary Objective(s)</h2><div></div><div class=""><h3 id="section-9.2.1">9.2.1&nbspStatistical Model, Hypothesis, and Method of Analysis</h3><div></div></div><div class=""><h3 id="section-9.2.2">9.2.2&nbspHandling of Intercurrent Events of Primary Estimand(s)</h3><div></div></div><div class=""><h3 id="section-9.2.3">9.2.3&nbspHandling of Missing Data</h3><div></div></div><div class=""><h3 id="section-9.2.4">9.2.4&nbspSensitivity Analysis</h3><div></div></div><div class=""><h3 id="section-9.2.5">9.2.5&nbspSupplementary Analysis</h3><div></div></div></div><div class=""><h2 id="section-9.3">9.3&nbspAnalysis Supporting Secondary Objective(s)</h2><div></div></div><div class=""><h2 id="section-9.4">9.4&nbspAnalysis of Exploratory Objective(s)</h2><div></div></div><div class=""><h2 id="section-9.5">9.5&nbspSafety Analyses</h2><div></div></div><div class=""><h2 id="section-9.6">9.6&nbspOther Analyses</h2><div></div></div><div class=""><h2 id="section-9.7">9.7&nbspInterim Analyses</h2><div></div></div><div class=""><h2 id="section-9.8">9.8&nbspSample Size Determination</h2><div></div></div><div class=""><h2 id="section-9.9">9.9&nbspProtocol Deviations</h2><div></div></div></div><div class="page"><h1 id="section-10">10&nbspGENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT</h1><div></div><div class=""><h2 id="section-10.1">10.1&nbspRegulatory and Ethical Considerations</h2><div></div></div><div class=""><h2 id="section-10.2">10.2&nbspCommittees</h2><div></div></div><div class=""><h2 id="section-10.3">10.3&nbspInformed Consent Process</h2><div></div></div><div class=""><h2 id="section-10.4">10.4&nbspData Protection</h2><div></div></div><div class=""><h2 id="section-10.5">10.5&nbspEarly Site Closure or Trial Termination</h2><div></div></div></div><div class="page"><h1 id="section-11">11&nbspGENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE</h1><div></div><div class=""><h2 id="section-11.1">11.1&nbspQuality Tolerance Limits</h2><div></div></div><div class=""><h2 id="section-11.2">11.2&nbspData Quality Assurance</h2><div></div></div><div class=""><h2 id="section-11.3">11.3&nbspSource Data</h2><div></div></div></div><div class="page"><h1 id="section-12">12&nbspAPPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY</h1><div></div><div class=""><h2 id="section-12.1">12.1&nbspFurther Details and Clarifications on the AE Definition</h2><div></div></div><div class=""><h2 id="section-12.2">12.2&nbspFurther Details and Clarifications on the SAE Definition</h2><div></div></div><div class=""><h2 id="section-12.3">12.3&nbspSeverity</h2><div></div></div><div class=""><h2 id="section-12.4">12.4&nbspCausality</h2><div></div></div></div><div class="page"><h1 id="section-13">13&nbspAPPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS</h1><div></div><div class=""><h2 id="section-13.1">13.1&nbspContraception and Pregnancy Testing</h2><div></div><div class=""><h3 id="section-13.1.1">13.1.1&nbspDefinitions Related to Childbearing Potential</h3><div></div></div><div class=""><h3 id="section-13.1.2">13.1.2&nbspContraception</h3><div></div></div><div class=""><h3 id="section-13.1.3">13.1.3&nbspPregnancy Testing</h3><div></div></div></div><div class=""><h2 id="section-13.2">13.2&nbspClinical Laboratory Tests</h2><div></div></div><div class=""><h2 id="section-13.3">13.3&nbspCountry/Region-Specific Differences</h2><div></div></div><div class=""><h2 id="section-13.4">13.4&nbspPrior Protocol Amendments</h2><div></div></div></div><div class="page"><h1 id="section-14">14&nbspAPPENDIX: GLOSSARY OF TERMS</h1><div></div></div><div class="page"><h1 id="section-15">15&nbspAPPENDIX: REFERENCES</h1><div></div></div></body></html>